NCT06874114 (RE-ENGAGE) is a clinical trial in Metastatic Hormone-sensitive Prostate Cancer, sponsored by Bayer.

Who is sponsoring NCT06874114?

NCT06874114 is sponsored by Bayer.

What condition does NCT06874114 study?

NCT06874114 studies Metastatic Hormone-sensitive Prostate Cancer.

Is NCT06874114 still recruiting?

NCT06874114 is currently active, enrolled. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT06874114: RE-ENGAGE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Observational Study to Learn More About Treatment Patterns and Factors Determining the Choice of Treatment in Canadian Men With Metastatic Hormone Sensitive Prostate Cancer in Routine Medical Care

Active, enrolled Last updated 13 April 2026

What this trial tests

trial in Metastatic Hormone-sensitive Prostate Cancer in 700 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

28 February 2025

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	Bayer
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	700
Start date	28 February 2025
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	1 location across Canada

Conditions studied

Metastatic Hormone-sensitive Prostate Cancer — all drugs for Metastatic Hormone-sensitive Prostate Cancer →

Sponsor

Bayer — full company profile →

Who can join

18 and older, male only, with Metastatic Hormone-sensitive Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational study in which only data are collected from adult Canadian men with metastatic hormone sensitive prostate cancer (mHSPC) are studied. Participants will not receive any advice on treatment or any changes to the healthcare. Metastatic hormone sensitive prostate cancer is a cancer of the prostate gland, a male reproductive gland found below the bladder. Metastatic means that cancer has spread to other parts of the body. Hormone-sensitive means it can be treated with anti-hormonal therapy such as androgen deprivation therapy (ADT). ADT lowers the level of testosterone and slows down the growth of cancer cells. However, in some cases, ADT alone is not sufficient and doctors recommend combining it with treatments like Androgen Receptor Pathway Inhibitors (ARPi) and/or docetaxel to stop the growth of cancer cells. ARPi slow down the growth of the cancer cells by blocking a sex hormone called the androgens from attaching to the protein found in the cancer cells. ARPi includes medicines like apalutamide, darolutamide, and enzalutamide. Docetaxel is a medicine used to treat different types of cancer and works by stopping the growth and spread of cancer cells. ADT, ARPi, and docetaxel are approved treatments for men with mHSPC in Canada. The participants in this study are already receiving treatment for mHSPC as part of their routine medical care from their doctors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Metastatic Hormone-sensitive Prostate Cancer

Currently open trials in the same condition.

NCT07451002 — A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France · recruiting
NCT06991556 — An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic H · Phase 2 · recruiting
NCT06334120 — An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea · recruiting
NCT05901649 — A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation · active not recruiting
NCT05818683 — A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer · Phase 1 · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06874114 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06874114.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing